ERBB2 and colorectal carcinoma: It has been described that high ERBB2 expression levels detected by immunohistochemistry were associated with cetuximab resistance in metastatic CRC and that the presence of the R784G mutation, which lies within the protein kinase domain of the protein, correlated with lower survival rate [118].